P3 Health Partners Swings To Q2 Profit, Lifts 2026 Guidance; Stock Up
P3 Health Partners (PIII) reported Q2 2026 revenue of $386.4 million, up 9% from $355.8 million a year earlier, and swung to net income of $15.7 million versus a $43.7 million loss. Adjusted EBITDA was $54.4 million. The company raised FY2026 guidance to $80-$110 million adjusted EBITDA and $1.5-$1.6 billion revenue.
How this was made
The 30-second read
Why it matters
The key tradable change is the raised FY2026 adjusted EBITDA outlook alongside a Q2 swing to net income and improved adjusted EBITDA, which can shift expectations for profitability trajectory through 2H 2026.
Market read
A same-day guidance raise with detailed profitability metrics is a direct catalyst for PIII positioning, especially for traders focused on healthcare services margin expansion.
What to watch
The article highlights a separation between reported medical margin and medical margin excluding favorable payer settlements and prior-year development, which could signal less repeatability than headline margins imply.
Background
P3 Health Partners operates physician-led networks focused on value-based care and reports results using medical margin, PMPM metrics, and at-risk membership.
Ticker impact
P3 Health Partners reported Q2 2026 results and raised FY2026 adjusted EBITDA guidance to $80-$110 million from an FY2025 loss.
Bullish bias for the next several sessions, with follow-through dependent on whether investors focus on margin expansion versus membership contraction.
The article provides concrete Q2 profitability metrics (net income swing, adjusted EBITDA improvement) plus a specific FY2026 guidance increase, which typically drives re-rating. However, it also notes at-risk membership fell ~10% YoY, which can temper the magnitude of the positive reaction.
Market effects
Value-based care and population management peers may see read-across on margin durability and contract/network restructuring effectiveness.
Limited direct regional impact; company is Nevada-based but revenue is tied to payer/provider networks.
Low global relevance; primarily a US healthcare services read-through.
Counterpoint
Investors may discount the guidance raise if the profitability improvement is partly driven by favorable payer settlements or one-time items, and if membership rationalization continues to pressure scale.
Key entities
- companyP3 Health Partners Inc.
Reported Q2 2026 revenue growth, swung to net income, and raised FY2026 guidance for adjusted EBITDA, revenue, and medical margin.
- executiveDr. Aric Coffman
CEO cited structural improvements across contracts, networks, and operations as the basis for the guidance raise.
